LA
JSPRW icon

Linden Advisors’s Japer Therapeutics Warrants JSPRW Stock Holding History

Linden Advisors’s Portfolio JSPRW Stock Details JSPRW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-32,603
Closed -$38K – 647
2021
Q2 		$38K Sell
32,603
-31,243
-49% -$29.6K ﹤0.01% 812
2021
Q1 		$53K Sell
63,846
-1,841
-3% -$2.69K ﹤0.01% 707
2020
Q4 		$97K Hold
65,687
– – ﹤0.01% 473
2020
Q3 		$77K Hold
65,687
– – ﹤0.01% 313
2020
Q2 		$69K Hold
65,687
– – ﹤0.01% 254
2020
Q1 		$36K Buy
+65,687
New +$51.6K ﹤0.01% 234

Other funds holding JSPRW

OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return
SCM
Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
ZA
Zazove Associates Incline Village, Nevada $1.22B AUM 1.91% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
BI
Bulldog Investors Saddle Brook, New Jersey $445M AUM 2.55% 1-Year Est. Return
Walleye Trading
Walleye Trading New York $60B AUM 42.19% 1-Year Est. Return

Linden Advisors's JSPRW Position: Q3 2021 in Review

Linden Advisors sold out of Japer Therapeutics Warrants (JSPRW) in Q3 2021, closing a stake of 32,603 shares — an estimated $38K sold.

Linden Advisors first reported a position in JSPRW in Q1 2020 and held it in 6 quarters. The position peaked at $97K in Q4 2020. 16 funds tracked by Wall St. Rank hold JSPRW as of Q3 2021.

  • Linden Advisors reported no remaining Japer Therapeutics Warrants position as of Q3 2021 after selling out during the quarter.
  • Linden Advisors sold 32,603 Japer Therapeutics Warrants shares in Q3 2021, an estimated $38K.
  • Linden Advisors first reported a position in Japer Therapeutics Warrants in Q1 2020 and held it in 6 quarters.
  • Linden Advisors's Japer Therapeutics Warrants position peaked at $97K in Q4 2020.
  • 16 funds tracked by Wall St. Rank held Japer Therapeutics Warrants as of Q3 2021.

Based on Linden Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.